Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma Clinical Trial

Official title:
Phase II Clinical Study of Cadonilimab Combination With Chemotherapy With or Without the Anti-CD47 Antibody AK117 Neoadjuvant/Adjuvant Therapy for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Status Recruiting

Clinical Trial Summary

This trial is a Phase II study. All patients are resectable Gastric or Gastroesophageal Junction Adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status 0-1.The purpose of this study is to evaluate the efficacy and safety of cadonilimab combined with chemotherapy with or without AK117 neoadjuvantin treatment of resectable Gastric or Gastroesophageal Junction Adenocarcinoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Adenocarcinoma
Esophageal Neoplasms
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Clinical Trial Details

NCT number	NCT05960955
Study type	Interventional
Source	Akeso
Contact	Weifeng Song, MD
Phone	+86(0760)89873999
Email	clinicaltrials@akesobio.com
Status	Recruiting
Phase	Phase 2
Start date	November 13, 2023
Completion date	November 30, 2027

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04221555` - Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2